Skip to main content
Caplight Logo









Ambagon Therapeutics

Ambagon Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.ambagontx.com/

Last Round

Series A

Jan 6, 2022

Total Funding Raised

$103M

Company Overview

Ambagon Therapeutics is a biotechnology company that develops small-molecule cancer drugs by stabilizing the interaction of 14-3-3 proteins with oncogenic client proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular gluedrug discoveryprotein-protein interactionsundruggable targetstargeted protein degradationTPDoncology researchstructural biologybiotech partnerships14-3-3 proteinscomputational drug discoveryprotein stabilizationdrug discovery platformpre-clinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ambagon Therapeutics Comparables

Compare Ambagon Therapeutics with similar companies based on industry and business-model similarity.

Ambagon Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Magnet Biomedicine
92%
Plexium
89%
SEED Therapeutics
88%

Ambagon Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 6, 2022
SeedJul 1, 2020

Ambagon Therapeutics Investors

Notable investors and investment history

Ambagon Therapeutics investors
InvestorRounds
Surveyor CapitalSeries A
RA Capital ManagementSeries A, Seed
Droia VenturesSeed, Series A
BioInnovation CapitalSeries A
AbbVie VenturesSeed, Series A
CitadelSeries A
Inkef CapitalSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2022

    $85M round led by Nextech Invest.

  • Jul 1, 2020

    $18M round led by RA Capital Management.

Ambagon Therapeutics Filings

Explore SEC and related filing metadata, where available.

Ambagon Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ambagon Therapeutics's valuation, stock price, and market status.

Is Ambagon a public or private company?

Ambagon is a private company.

What is the current stock price of Ambagon?

Ambagon is a private company with no public stock price. No recent secondary market data is available.

How much is Ambagon worth (valuation)?

Valuation information for Ambagon is not publicly available.

Can I buy Ambagon stock?

Ambagon shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ambagon's last funding round?

Ambagon's most recent funding round was Series A on January 6, 2022.

Who are the main investors in Ambagon?

Key investors in Ambagon include RA Capital Management, Nextech Invest.

Will Ambagon IPO soon?

No public IPO plans have been announced for Ambagon.

How can I track Ambagon secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ambagon's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range12
Year Founded2020
Last FundingJan 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?